Microcrystalline Chitosan is Ineffective to Decrease Plasma Lipids in both Apolipoprotein E epsilon4 Carriers and Non-Carriers: A Long-Term Placebo-Controlled Trial in Hypercholesterolaemic Volunteers
| Autor: | Erkki Wuolijoki, Riikka Rontu, Terho Lehtimäki, Saara Metso, Pauli Ylitalo, Ritva Ylitalo, Matti Nikkil |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Blood Glucose Male Apolipoprotein E Heterozygote medicine.medical_specialty Adolescent Genotype Apolipoprotein E4 Hypercholesterolemia Placebo-controlled study Toxicology Placebo chemistry.chemical_compound Apolipoproteins E Double-Blind Method Internal medicine Blood plasma medicine Humans Volunteer Aged Hypolipidemic Agents Pharmacology Diminution Chitosan Cross-Over Studies Chemistry Cholesterol General Medicine Middle Aged Lipids Endocrinology Female lipids (amino acids peptides and proteins) Lipoprotein |
| Zdroj: | Basic Toxicology. 97:98-103 |
| ISSN: | 1742-7843 1742-7835 |
| DOI: | 10.1111/j.1742-7843.2005.pto_111.x |
| Popis: | Chitosan is a deacetylated product of chitin. Microcrystalline form of chitosan has a large adsorption area claimed to decrease gastrointestinal absorption of cholesterol. However, the long-term effect of chitosan on plasma lipids is variable, the averaged influence being negligible or lacking in mildly-to-moderately hypercholesterolaemic (4.8-6.8 mmol/l) subjects. We evaluated whether this variation and inefficacy depend on apolipoprotein E genotype. 130 middle-aged, otherwise healthy men (n=55) and women (n=75) were randomized into two treatment groups for a 7 month trial. During a 1 month run-in period all participants received placebo. Subsequently, one half first took placebo twice daily for 3 months and then 1.2 g chitosan twice daily for 3 months, and the other half vice versa in a cross-over way. Altogether 84 participants completed the study. Plasma lipids and glucose were determined at the end of each phase of the study, and all subjects undergone to the cross-over phases were apolipoprotein E genotyped. Chitosan altered plasma total, low- and high density cholesterol, triglycerides, and blood glucose in neither apolipoprotein E epsilon 4 allele carriers (n=29) nor non-carriers (n=55), compared to placebo. In conclusions, chitosan is ineffective to decrease plasma lipids in apolipoprotein E epsilon 4 carrier and non-carrier phenotypes with mildly-to-moderately increased plasma cholesterol. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|